Carbapenem-Resistant Enterobacteriaceae

Alina Iovleva, Yohei Doi

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.

Original languageEnglish
Pages (from-to)303-315
Number of pages13
JournalClinics in Laboratory Medicine
Volume37
Issue number2
DOIs
Publication statusPublished - 01-06-2017
Externally publishedYes

Fingerprint

Carbapenems
Enterobacteriaceae
Polymyxins
Aminoglycosides
Anti-Bacterial Agents
Safety
Enzymes

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Iovleva, Alina ; Doi, Yohei. / Carbapenem-Resistant Enterobacteriaceae. In: Clinics in Laboratory Medicine. 2017 ; Vol. 37, No. 2. pp. 303-315.
@article{82618ec6e07845c3bc07b34542918978,
title = "Carbapenem-Resistant Enterobacteriaceae",
abstract = "Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.",
author = "Alina Iovleva and Yohei Doi",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.cll.2017.01.005",
language = "English",
volume = "37",
pages = "303--315",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Carbapenem-Resistant Enterobacteriaceae. / Iovleva, Alina; Doi, Yohei.

In: Clinics in Laboratory Medicine, Vol. 37, No. 2, 01.06.2017, p. 303-315.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Carbapenem-Resistant Enterobacteriaceae

AU - Iovleva, Alina

AU - Doi, Yohei

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.

AB - Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.

UR - http://www.scopus.com/inward/record.url?scp=85014749179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014749179&partnerID=8YFLogxK

U2 - 10.1016/j.cll.2017.01.005

DO - 10.1016/j.cll.2017.01.005

M3 - Review article

C2 - 28457352

AN - SCOPUS:85014749179

VL - 37

SP - 303

EP - 315

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 2

ER -